User login
The wearable external cardiac defibrillator for cancer patients at risk for sudden cardiac death
Implantable cardioverter defibrillators (ICDs) are indicated for primary prevention of sudden cardiac death (SCD) in patients with reduced left ventricular function (an ejection fraction of ≤ 35%). ICD therapy is also recommended for secondary prevention of SCD in patients with a life-threatening cardiac arrhythmia, including aborted sudden cardiac death. Contraindications to ICD therapy are life expectancy ≤ 1 year, incessant arrhythmia, significant psychiatric illness, syncope without evidence of inducible ventricular arrhythmia or structural heart disease, ventricular arrhythmia amenable to catheter ablation, ventricular arrhythmia due to a reversible cause, and primary prevention of SCD in patients ineligible for cardiac transplantation or cardiac resynchronization therapy.1 In addition, relative contraindications to ICD therapy include the need for radiation therapy to the thorax, high risk for infection, and high risk for deep venous thrombosis.
A subset of patients with cancer is at risk for SCD due to a variety of cardiac causes, including chemotherapy-induced cardiomyopathy or druginduced long QT syndrome. These patients may benefit from ICD placement. However, the aforementioned relative contraindications for permanent defibrillator implantation often coexist in patients with cancer. Moreover, an individual with acute malignancy may have other contraindications for permanent defibrillator implantation, including the potential reversibility of cardiomyopathy or arrhythmia or an unclear prognosis for 1-year survival. ...
* For a PDF of the full article, click in the link to the left of this introduction.
Implantable cardioverter defibrillators (ICDs) are indicated for primary prevention of sudden cardiac death (SCD) in patients with reduced left ventricular function (an ejection fraction of ≤ 35%). ICD therapy is also recommended for secondary prevention of SCD in patients with a life-threatening cardiac arrhythmia, including aborted sudden cardiac death. Contraindications to ICD therapy are life expectancy ≤ 1 year, incessant arrhythmia, significant psychiatric illness, syncope without evidence of inducible ventricular arrhythmia or structural heart disease, ventricular arrhythmia amenable to catheter ablation, ventricular arrhythmia due to a reversible cause, and primary prevention of SCD in patients ineligible for cardiac transplantation or cardiac resynchronization therapy.1 In addition, relative contraindications to ICD therapy include the need for radiation therapy to the thorax, high risk for infection, and high risk for deep venous thrombosis.
A subset of patients with cancer is at risk for SCD due to a variety of cardiac causes, including chemotherapy-induced cardiomyopathy or druginduced long QT syndrome. These patients may benefit from ICD placement. However, the aforementioned relative contraindications for permanent defibrillator implantation often coexist in patients with cancer. Moreover, an individual with acute malignancy may have other contraindications for permanent defibrillator implantation, including the potential reversibility of cardiomyopathy or arrhythmia or an unclear prognosis for 1-year survival. ...
* For a PDF of the full article, click in the link to the left of this introduction.
Implantable cardioverter defibrillators (ICDs) are indicated for primary prevention of sudden cardiac death (SCD) in patients with reduced left ventricular function (an ejection fraction of ≤ 35%). ICD therapy is also recommended for secondary prevention of SCD in patients with a life-threatening cardiac arrhythmia, including aborted sudden cardiac death. Contraindications to ICD therapy are life expectancy ≤ 1 year, incessant arrhythmia, significant psychiatric illness, syncope without evidence of inducible ventricular arrhythmia or structural heart disease, ventricular arrhythmia amenable to catheter ablation, ventricular arrhythmia due to a reversible cause, and primary prevention of SCD in patients ineligible for cardiac transplantation or cardiac resynchronization therapy.1 In addition, relative contraindications to ICD therapy include the need for radiation therapy to the thorax, high risk for infection, and high risk for deep venous thrombosis.
A subset of patients with cancer is at risk for SCD due to a variety of cardiac causes, including chemotherapy-induced cardiomyopathy or druginduced long QT syndrome. These patients may benefit from ICD placement. However, the aforementioned relative contraindications for permanent defibrillator implantation often coexist in patients with cancer. Moreover, an individual with acute malignancy may have other contraindications for permanent defibrillator implantation, including the potential reversibility of cardiomyopathy or arrhythmia or an unclear prognosis for 1-year survival. ...
* For a PDF of the full article, click in the link to the left of this introduction.